Radium chloride [223Ra] for patients with prostate cancer and skeletal metastases. Clinical recommendations

Cover Page

Cite item

Full Text

Abstract

Radiopharmaceuticals previously used to treat patients with metastatic castrate-resistant prostate cancer and skeletal metastases were positioned as means to suppress pain, reduce analgesics consumption and improve the quality of life. They were usually administered once in case of progressive pain syndrome. Radium chloride [223Ra] is registered to treat patients with castrate-resistant prostate cancer and multiple skeletal metastases, but without visceral metastases. The ALSYMPCA study showed a significantly increased overall survival in the group receiving radium chloride [223Ra] compared with placebo. This became the basis to register the drug, as well as to include the treatment into the clinical guidelines of professional associations in various countries of the world. The secondary endpoints of the ALSYMPCA study were evaluation of the quality of life, the influence of radium chloride [223Ra] on pain severity, the dynamics of tumor and biochemical markers, and the time to the first skeleton associated complication. Thus, the main goal of radium chloride [223Ra] therapy is to prolong patients’ life, and it can be prescribed to those with or without pain syndrome. The data served as the basis for widespread use of radium chloride [223Ra] to treat patients with castrate-resistant prostate cancer and skeletal metastases

About the authors

T Yu. Kochetova

A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia

Author for correspondence.
Email: at_mail@inbox.ru
ORCID iD: 0000-0002-7809-1059
4 Koroleva St., Obninsk 249031 Russian Federation

V. V. Krylov

A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia

ORCID iD: 0000-0001-6655-5592
4 Koroleva St., Obninsk 249031 Russian Federation

K. M. Petrosyan

A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia

ORCID iD: 0000-0002-5502-5710
4 Koroleva St., Obninsk 249031 Russian Federation

O. B. Karyakin

A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia

ORCID iD: 0000-0002-6112-2840
4 Koroleva St., Obninsk 249031 Russian Federation

V. A. Biryukov

A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia

ORCID iD: 0000-0002-6750-521X
4 Koroleva St., Obninsk 249031 Russian Federation

B. Ya. Alekseev

National Medical Research Radiological Center, Ministry of Health of Russia

ORCID iD: 0000-0002-3398-4128
4 Koroleva St., Obninsk 249031 Russian Federation

V. B. Matveev

N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia

ORCID iD: 0000-0001-7748-9527
24 Kashirskoe Shosse, Moscow 115478 Russian Federation

S. A. Ivanov

A.F. Tsyb Medical Radiological Research Center – branch of the National Medical Research Radiological Center, Ministry of Health of Russia

4 Koroleva St., Obninsk 249031 Russian Federation

A. D. Kaprin

National Medical Research Radiological Center, Ministry of Health of Russia

ORCID iD: 0000-0001-8784-8415
4 Koroleva St., Obninsk 249031 Russian Federation

References

  1. Henriksen G., Breistol K., Bruland O.S. et al. Significant antitumor effect from boneseeking, alpha-particle-emitting Ra-223 demonstrated in an experimental skeletal metastases model. Cancer Res 2002;62(11):3120–5.
  2. Nosov D.A., Gladkov O.A., Koroleva I.A. et al. Practical recommendations for the medicinal treatment of prostate cancer. Malignant tumors: practical recommendations RUSSCO #3s2, 2018 (Vol. 8). Pp. 458–470. (In Russ.).
  3. Parker C., Nilsson S., Heinrich D. et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 2013;369(3):213–23. doi: 10.1056/NEJMoa1213755.
  4. Hoskin P., Sartor O., O’Sullivan J.M. et al. Efficacy and safety of radium-223 dichloride in patients with castration-resistant prostate cancer and symptomatic bone metastases, with or without previous docetaxel use: a prespecified subgroup analysis from the randomised, doubleblind, phase 3 ALSYMPCA trial. Lancet Oncol 2014;15(12):1397–406. doi: 10.1016/S1470-2045(14)70474-7.
  5. Smith H.S. Painful osseous metastases. Pain Physician 2011;14:E373–403.
  6. Heidenreich A., Bastian P.J., Bellmunt J. et al. EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014;65(2):467–79. doi: 10.1016/j.eururo.2013.11.002.
  7. Parker C., Gillessen S., Heidenreich A., Horwich A. Cancer of the prostate: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015;26:v69–77. doi: 10.1093/annonc/mdv222.
  8. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: prostate cancer version 2.2016. Fort Washington, PA: National Comprehensive Cancer Network, 2016.
  9. Sartor O., Coleman R., Nilsson S. et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol 2014;15(7):738–46. doi: 10.1016/S1470-2045(14)70183-4.
  10. Parker C., Finkelstein S.E., Michalski J.M. et al. Efficacy and safety of radium-223 dichloride in symptomatic castrationresistant prostate cancer patients with or without baseline opioid use from the phase 3 ALSYMPCA trial. Eur Urol 2016;70(5):875–83. doi: 10.1016/j.eururo. 2016.06.002.
  11. Cookson M.S., Roth B.J., Dahm P. et al. Castration-resistant prostate cancer: AUA guideline. American Urological Association. Available at: https://www.auanet.org/guidelines/castration-resistant-prostatecancer.
  12. Sartor A.O., Amariglio R., Wilhelm S. et al. Correlation between baseline variables and survival in the radium-223 dichloride (Ra-223) phase III ALSYMPCA trial with attention to total ALP changes. J Clin Oncol 2013;31:5080.
  13. Xofigo (radium-223 dichloride). Summary of Product Characteristics. Berlin, Germany: Bayer Pharma AG, 2016.
  14. Morris M.J., Higano C.S., Scher H.I. et al. Effects of radium-223 dichloride (Ra-223) with docetaxel (D) vs D on prostate-specific antigen (PSA) and bone alkaline phosphatase (bALP) in patients (pts) with castration-resistant prostate cancer (CRPC) and bone metastases (mets): a phase 1/2a clinical trial [abstract]. J Clin Oncol 2015;33:abstr 5012.
  15. Saad F., Carles J., Gillessen S. et al. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial. Lancet Oncol 2016;17(9):1306–16. doi: 10.1016/S1470-2045(16)30173-5.
  16. Maughan B.L., Luber B., Nadal R., Antonarakis E.S. Comparing sequencing of abiraterone and enzalutamide in men with metastatic castration-resistant prostate cancer: a retrospective study. Prostate 2017;77(1):33–40. doi: 10.1002/pros.23246.
  17. Pezaro C.J., Omlin A., Lorente D. et al. Visceral disease in castration-resistant prostate cancer. Eur Urol 2014;65(2):270–3. doi: 10.1016/j.eururo.2013.10.055.
  18. Sartor O., Hoskin P., Coleman R.E. et al. Chemotherapy following radium-223 dichloride treatment in ALSYMPCA. Prostate 2016;76(10):905–16. doi: 10.1002/pros.23180.
  19. O’Sullivan J.M. ECC abstract 2561. Eur J Cancer 2015;51:S497–8.
  20. Xofigo (radium-223 dichloride). Full Prescribing Information, Bayer Health Care Pharmaceuticals Inc., Wayne, NJ, USA, 2013.
  21. http://pharma.bayer.ru/scripts/pages/ru/catalog/xofigo.php.
  22. Gillessen S., Omlin A., Attard G. et al. Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015. Ann Oncol 2015;26(8):1589–604. doi: 10.1093/annonc/mdv257.
  23. Keizman D., Fosboel M.O., Reichegger H. et al. Imaging response during therapy with radium-223 for castration-resistant prostate cancer with bone metastasesanalysis of an international multicenter database. Prostate Cancer Prostatic Dis 2017;20(3):289–93. doi: 10.1038/pcan.2017.6.
  24. Blackledge M.D., Kohl D.M., Collins D.J. et al. Assessing response heterogeneity following radium 223 administration using whole body diffusion weighted MRI. Presented at: International Society for Magnetic Resonance in Medicine 25th Annual Meeting & Exhibition. April 22–27, 2017; Honolulu, HI.
  25. Belozerova M.S., Kochetova T.Yu., Krylov V.V. Practical recommendations for radionuclide therapy for bone metastases. Zlokachestvennye opukholi = Malignant Tumors 2015(4, special issue 2): 448–54. (In Russ.).
  26. Kairemo K., Joensuu T., Rasulova N. et al. Evaluation of alpha-therapy with radium223-dichloride in castration resistant metastatic prostate cancer – the role of gamma scintigraphy in dosimetry and pharmacokinetics. Diagnostics (Basel) 2015;5(3):358–68. doi: 10.3390/diagnostics5030358.
  27. Basch E., Loblaw D.A., Oliver T.K. et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol 2014;32(30):3436–48. doi: 10.1200/JCO.2013.54.8404.
  28. Scher H.I., Fizazi K., Saad F. et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012;367(13):1187–97. doi: 10.1056/NEJMoa1207506.
  29. Krylov V.V., Kochetova T.Yu., Belozerova M.S., Voloznev L.V. Features the application of different radiopharmaceuticals in patients with bone metastases. Palliativnaya meditsina i reabilitatsiya = Palliative Medicine and Rehabilitation 2015;(4):26–33. (In Russ.).

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36986 от  21.07.2009.